Methods Retrospective audit of referrals from 2010–2013. Data collected from electronic medical records: presence of RF, age, sex, length of survival from diagnosis, and NIV use.

Results Referrals: 99 from 2010–2013 vs. 38 from 2007–2010 and only 12 from 1999–2002. Of the 99, 35 had RF at referral and 14 developed RF during follow-up. 89% patients referred from Neurology. 88% patients with RF elected to be treated with NIV. Length of survival (mean±SEM) in the RF-NIV group was 536±48 days vs. 206±128 in RF-non-NIV-group (p=0.033) and non-RF group: 532±65 days.

Conclusions Referrals to WoSLTVU increased significantly following NICE guideline publication. NIV lengthened survival by 11 months. This highlights the importance of respiratory support and need for early engagement with respiratory services for the multidisciplinary care of MND patients.

REFERENCES